Skip to main
ZYME

Zymeworks Inc (ZYME) Stock Forecast & Price Target

Zymeworks Inc (ZYME) Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 56%
Buy 44%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Zymeworks Inc is recognized for its innovative approach to biotherapeutics, particularly through its therapeutic platforms that support the development of differentiated candidates like the HER2-targeted bispecific antibody zanidatamab. Recent clinical findings indicate that Ziihera, in combination with chemotherapy, has demonstrated statistically significant improvements in progression-free survival and overall survival, alongside a favorable safety profile, which could support peak risk-adjusted sales estimates of up to $1.5 billion. The company's transition towards a royalty-driven business model, bolstered by strong cash reserves and upcoming milestone payments, positions Zymeworks to leverage its R&D capabilities while establishing solid revenue streams in the competitive biopharmaceutical landscape.

Bears say

Zymeworks Inc faces significant challenges that contribute to a negative outlook on its stock, primarily due to the potential for clinical trial failures related to the efficacy and safety of its core assets, including zanidatamab. Furthermore, the company is at risk of manufacturing scalability issues, delayed regulatory approvals in Europe, and potentially poor commercial uptake, which could severely impact revenue generation. Additionally, Zymeworks' heavy reliance on capital markets for financing creates vulnerability, as unfavorable market conditions or unsuccessful capital raises could lead to financial instability or long-term dilution, further pressuring the stock price.

Zymeworks Inc (ZYME) has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 56% of analysts recommend a Strong Buy, 44% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Zymeworks Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Zymeworks Inc (ZYME) Forecast

Analysts have given Zymeworks Inc (ZYME) a Strong Buy based on their latest research and market trends.

According to 9 analysts, Zymeworks Inc (ZYME) has a Strong Buy consensus rating as of Dec 31, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32.44, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32.44, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Zymeworks Inc (ZYME)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.